Welcome to our dedicated page for Organigram Global SEC filings (Ticker: OGI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings for Organigram Global Inc. (NASDAQ: OGI, TSX: OGI) provide structured insight into the company’s operations as a Canadian cannabis cultivator and manufacturer. As a foreign private issuer, Organigram files reports such as Form 40-F and Form 6-K with the U.S. Securities and Exchange Commission. Recent Form 6-K filings reference press releases, condensed consolidated interim unaudited financial statements, management’s discussion and analysis, and officer certifications for periods including the three and nine months ended June 30, 2025.
Through these filings, readers can access detailed information on Organigram’s financial performance, including net revenue, cost of sales, gross margin, adjusted gross margin, adjusted EBITDA and free cash flow, as well as balance sheet metrics such as cash, inventories, total assets, liabilities and shareholders’ equity. The filings also discuss non-IFRS financial measures, explaining how management uses these metrics to assess the company’s financial and operational results, and provide reconciliations to IFRS figures.
Organigram’s SEC submissions frequently include news releases that cover topics such as record quarterly and annual results, acquisitions like Motif Labs Ltd. and Collective Project Limited, international sales growth, and developments in hemp-derived THC and cannabinoid beverages. They also capture governance and leadership updates, including CEO succession plans and executive appointments, and describe the company’s regulatory context under the Cannabis Act and Cannabis Regulations in Canada.
On Stock Titan’s filings page for OGI, users can review these SEC documents as they are furnished to EDGAR and use AI-powered tools to help interpret complex sections. This includes quickly identifying key themes in earnings discussions, understanding changes in non-IFRS measures, and locating disclosures related to international expansion, extraction and processing facilities, and brand portfolio developments. The filings page also offers access to current reports on Form 6-K that incorporate significant press releases, providing a consolidated view of Organigram’s regulatory and disclosure history.